Cancer survivors are at a high risk for treatment-related late effects, particularly neurocognitive impairment in the attention and executive function domains. These can be compounded in pediatric populations still undergoing neural development, which has increased interest in survivorship studies and neurorehabilitation approaches to mitigate these effects. Cognitive training regimens have shown promise as a therapeutic intervention for improving cognitive function.
View Article and Find Full Text PDFAnnu Int Conf IEEE Eng Med Biol Soc
November 2021
The acquisition of neurophysiological data during awake, behaving animal experiments typically involves experimental sessions lasting several days to weeks. Therefore, it is important to understand natural fluctuations in behavioral performance over such periods. Here we quantified patterns of movement variability for reaches performed by two monkeys across five daily experimental sessions.
View Article and Find Full Text PDFAlthough multisensory integration is crucial for sensorimotor function, it is unclear how visual and proprioceptive sensory cues are combined in the brain during motor behaviors. Here we characterized the effects of multisensory interactions on local field potential (LFP) activity obtained from the superior parietal lobule (SPL) as non-human primates performed a reaching task with either unimodal (proprioceptive) or bimodal (visual-proprioceptive) sensory feedback. Based on previous analyses of spiking activity, we hypothesized that evoked LFP responses would be tuned to arm location but would be suppressed on bimodal trials, relative to unimodal trials.
View Article and Find Full Text PDFAnnu Int Conf IEEE Eng Med Biol Soc
July 2020
Multisensory integration is the process by which information from different sensory modalities is integrated by the nervous system. Understanding this process is important not only from a basic science perspective but also for translational reasons, e.g.
View Article and Find Full Text PDFIntroduction: The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo-controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60-year-old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non-carriers who receive placebo.
Methods: Of the 252 enrolled, we present data on a total of 242 mutation carriers and non-carriers matched by age range, excluding data on 10 participants to protect participant confidentiality, genetic status, and trial integrity.
Results: We summarize demographic, clinical, cognitive, and behavioral data from 167 mutation carriers and 75 non-carriers, 30 to 53 years of age.